CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an Envelope addressed to: Mail Stop Disclosure Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:)

Stefan Schorling Unassigned) Examiner:

SERIAL NO.: 10/587,386) ART UNIT: Unassigned

INTERNATIONAL FILING DATE: FEBRUARY, 8, 2005) Confirmation No. N/A

) DOCKET NO: 22398-US

NEW PRIMERS AND PROBES FOR

THE DETECTION OF PARVOVIRUS

B19

INFORMATION DISCLOSURE STATEMENT

Mail Stop Disclosure. Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Applicant submits herewith a Form-1449, in compliance with the duty of disclosure requirements of 37 C.F.R. §1.56, 1.97 and 1.98, listing accompanying documents that may be considered material to the examination of this application. This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits, whichever event occurs last. No certification or fee is therefore required under 37 C.F.R. § 1.97(b). However, should the Commissioner determine that fees are due in order for the Information Disclosure Statement to be considered at this stage, the Commissioner is hereby authorized to charge any fee deficiency, or credit any overpayment, to Deposit Account No. 50-0812.

This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

Consideration of the cited documents and making the same of record in the prosecution of the above-identified application is respectfully requested.

Respectfully submitted,

Date:

<u>Correspondence Address:</u> Roche Molecular Systems, Inc

1145 Atlantic Avenue Alameda, CA 94501 Tele: (510) 814-2800

Fax: (510) 814-2800

U.S. Department of Commerce Patent and Trademark Office LIST F INFORMATION CITED BY APPLICANT Use several sheets if necessary)				Atty. Docket No. 22398-US Serial No. 10/587.386 Applicant: Stefan Schorling					
				International Filing Date: February 5, 2005 Group: N/A					
3 <u>L1 - V U 2000</u>	لع		TIC DA'	TENT I	DOCUMENTS		-		
MAN	9—	DOCUMENT NUMBER	ISSUE		NAME	CLASS	SUBCLASS	FILIN	G DATE
INFFAL	1	4,458,066	07/03	3/84	Caruthers, et al.	536	27	03/	24/81
	2	4,996,143	02/26	5/91	Heller, et al.	435	6	04/	13/90
	3	5,130,238	07/14	1/92	Malek. et al.	435	91	08/	23/89
	4	5,210,015	05/11	1/93	Gelfand, et al.	435	6	08/	06/90
	5	5,386,024	01/31	/95	Kacian, et al.	536	25.4	02/	10/93
	6	5,478,972	12/26	· 6/95	Mizutani, et al.	174	250	08/	25/94
	7	5,487,972	01/30)/96	Gelfand, et al.	435	6	01/	05/93
	8	5,565,322	10/15	5/96	Heller, M	435	6	11,	/6/92
	9	5,585,254	12/17	7/96	Maxwell, et al.	435	172.3	04/	02/93
	10	5,804,375	09/08	3/98	Gelfand, et al.	435	6	04/	25/95
	11	5,849,489	12/15	5/98	Heller, M	435	6	08/	23/96
	12	6,103,476	08/15	5/00	Tyagi, et al.	435	6	03/	15/99
	13	6,162,603	12/19	9/00	Heller, M	435	6	07/	28/98
	14	6,174,670 B1	01/16	5/01	Wittwer, et al.	435	6	06/	04/97
	15	6,183,999 B1	02/06	5/01	Weimer, et al.	435	91.2	11/	24/98
	16	6,268,349 B1	07/31	1/01	Hirschman, S	514	44	04/	15/97
	17	6,274,307 B1	08/14	1/01	Soutschek, et al.	435	5	05/	15/97
	18	6,395,472 B1	05/28	3/02	Leary, et al.	435	5	02/	05/99
			<u> </u>	,			l		_
· · ·					T DOCUMENTS	CT A CC	L CAUDOT A CO		. A TUON
		DOCUMENT NUMBER	PUBLICA DA		COUNTRY	CLASS	SUBCLASS	YES	LATION
	19	PCT/EP2005/001243	05/31	1/05	РСТ			165	NO
		Search Report							
	20	37 24442 A1	02/02	2/89	DE				-
	21	37 34442 A1	04/27	7/89	DE				
	22	0 238 893 B1	03/02	2/87	EP				
	23	0 439 182 B1	01/25	5/91	EP				
	24	04 - 88985	03/23	3/92	JР				X
	25	11 - 221099	08/17	7/99	JP				Х
	26	WO 90/01069	02/08	3/90	PCT			<u> </u>	

				,			Ü		
	27	WO 91/04330	04/04/91	PCT					
	28	WO 91/12079	08/22/91	PCT					
	29	WO 92/02208 ·	05/29/92	PCT			 		
	30	WO 96/09391	03/28/96	PCT			-	<u> </u>	
	31	WO 96/41811	12/27/96	PCT				ļ <u></u>	
	32	WO 98/04730	02/05/98	PCT					
	33	WO 99/16781	04/08/99	PCT					
	34	WO 99/28439	06/10/99	PCT	-				
	35	WO 00/24917	05/04/00	PCT					
	36	WO 01/06019 A2	01/25/01	PCT	1	 			
	37	WO 01/14593 A2	03/01/01	PCT					
	38	WO 01/37291 A1	05/25/01	PCT					
	39	WO 02/00924 A2	01/0302	PCT					
	40	WO 03/002753 A2	01/09/03	PCT	,	<u> </u>			
	41	WO 2005/075686 A1	08/18/05	PCT	-				
	42	2 146 372 C1	10/03/00	RU					
	<u>!</u>			<u> </u>		.I		1	
	1 42	7		Title, Date, Pertine					
	43	Abramson, R., et al., 1 4:41-47	1993, "Nucleic aci	d amplification te	echnologie	s", Analytica	l Biotechr	iology,	
	44	Alderton, R., et al., 19	92, "Magnetic Be	ad Purification of	M13 DNA	Sequencin	g Templa	ites",	
		Analytical Biotechnolog	y, 201: 166-169			•			
	45	Anderson, M., et al., Letters to the Euror. Human Larvovirus, The Cause of Erythema							
		Infectiosum (Fifth Dis	sease)?", The Lanc	et, June 18, 1983, j	p. 1378				
	46	Astell, C., et al., 1987, "Structural and Functional Homology of Parvovirus and Papovavirus							
		Polypeptides", J.gen.Virol., 68: 885-893							
	47	Aubin, J., et al., 2000, "Large-Scale Screening for Human Parvovirus B19 DNA y PCR:							
		Application to the Qu	ality Control of I	Plasma for Fraction	nation", Vo	ox Sang, 78: 7	7-12		
	48						11		
	49	Barany, F., 1991, "The	Ligasa Chain Ra	action in a PCR W	Jorld" DC	D Mathada a	nd Amilia	ationa	
		1:5-16	Elgase Chair Re	action in a 1 CR V	voriu , r c.	K Wieinous u	пи Аррисі	utions,	
	50	Barany, F., 1991, "Genetic disease detection and DNA amplification using cloned							
		thermostable ligase", Proc. Natl. Acad Sci, 88:189-193							
	51	Beaucage, S., et al., 1981, "Deoxynucleoside Phosphoramidites - A New Class of Key							
		Intermediates for De	-	_			•	2	
$\overline{}$	1		7 - 7 - 7 - 7 - 7 - 7 - 7 - 7 - 7 - 7 -			·····		<u> </u>	
	52	Boom, R., et al., 1990,	"Rapid and Simr	ole Method for Pii	rification o	of Nucleic A	cids" In	irnal of	

Page 3 of 5

	53	Brown, E., et al., 1979, "Chemical Synthesis and Cloning of a Tyrosine tRNA Gene" Methods in
	54	Enzymology, 68(8):109-151
	34	Brown, K., 2000, "Haematological Consequences of Parvovirus B19 Infection", Bailliere's Clinical Haematology, 13(2):245-259
	55	Carriere, C., et al., 1993, "Rapid and sensitive method for the detection of B19 virus DNA
		using the polymerase chain reaction with nested primers", Journal of Virological Methods,
		44:221-234
	56	Cohen, B., 1995, "Parvovirus B19: an expanding spectrum of disease", BMJ, 311:1549-1552
	57	Cotmore, S., et al., 1986, "Identification of the major Structural and nonstructural Proteins
		Encoded by Human Parvovirus B19 and mapping of Their genes by Procaryotic Expression of
		Isolated Genomic Fragments", Journal of Virology, 60(2):548-557
	58	Cubie, H., et al., 1995, "Dot-blot hybridization assay for detection of parvovirus B19 infections
·		using synthetic oligonucleotides", Molecular and Cellular Probes, 9:59-66
	59	Dorsch, S., et al., 2001, "The VP1-unique region of parvovirus B19: amino acid variability and
		antigenic stability", Journal of General Virology, 82:191-199
	60	Düx, S., et al., 2002, "Parvovirus B19 Myocarditis in a young man with Previous non-bacterial
		meningitis", Dtsch Med Wochenschr, 127:1584-1588
	61	Enders, G., et al., 1998, "Life-Threatening Parvovirus B19-Associated Myocarditis and Cardiac
		Transplantation as Possible Therapy: Two Case Reports", Clinical Infectious Diseases, 26;355-
		358
	62	Enders, G., "Viral Infections of the Fetus Neonate, other than Rubella", Topley & Wilson's
		Microbiology and Microbial Infections, 9th Ed., by Collier, L., et al., Arnold Publishers 1998,
		pp 873-915
	63	Erdman, D., et al., 1996, "Genetic diversity of human parvovirus B19: sequence analysis of the
		VP1/VP2 gene from multiple isolates", Journal of General Virology, 77:2767-2774
	64	Garegg, P., et al., 1985, "Formation of Internucleotidic Bonds via Phosphonate Intermediates",
		Chemica Scripta, 25:280-282
	65	Gruber, F., et al., 2001, "Quantitation of Viral DNA by Real-Time PCR Applying Duplex
		Amplification, Internal Standardization, and Two-Color Fluorescence Detection", Applied and
		Environmental Microbiology, 67 (<u>6</u>):2837-2839
	66	Guatelli, J., et al., 1990, "Isothermal, in vitro amplification of nucleic acids by a multienzyme
		reaction modeled after retroviral replication", Proc. Natl. Acad. Sci. USA, 87:1874-1878
	67	Harder, T., et al., 2001, "New LightCycler PCR for Rapid and Sensitive Quantification of
		Parvovirus B19 DNA Guides Therapeutic Decision-Making in Relapsing Infections", Journal of
		Clinical Microbiology, 39 (<u>12</u>): 4413-4419
	68	Hemauer, A., 1996, "Sequence variability among different parvovirus B19 isolates", Journal of
		General Virology" 77:1781-1785
	69	Hicks, K., 1996, "Sequence analysis of a parvovirus B19 isolate and baculovirus expression of
		the non-structural protein", Archives Virology, 141:1319-1327
	70	Holloway, B., 1993, "An exonuclease-amplification coupled capture technique improves
		detection of PCR product", Nucleic Acids Research, 21(16):3905-3906
	71	Jakobi, R., 1988, "Filter-Supported Preparation of λ Phage DNA", Analytical Biochemistry
		175: 196-201
	72	Jordan, J., 1996, "Exonuclease-released Fluorescence Detection of Human Parvovirus B19
L		L

		DNA, Molecular Diagnosis, 1(4):321-328
	73	Junkind, D., 2001, "Automation of laboratory testing for infectious diseases using the
		polymerase chain reaction – our past, our present, our future", Journal of Clinical Virology, 20:1-
		6
	74	Kwoh, D., 1989, "Transcription-based amplification system and detection of amplified human
		immunodeficiency virus type 1 with a bead-based sandwich hybridization format", Proc. Natl.
		Acad. Sci. USA, 86:1173-1177
	75	Marko, M., 1982, "A Procedure for the Large-Scale Isolation of Highly Purified Plasmid DNA
		Using Alkaline Extraction and Binding to Glass Powder", Analytical Biochemistry, 121:382-387
	76	Müller, J., et al., 2002, "Development and Validation of a Real-Time PCR Assay for Routine
		testing of Blood Donations for Parvovirus B19 DNA", Infus Ther Transus Med, 29:254-258
	77	Narang, S., et al., 1979, "Improved Phosphotriester Method for the Synthesis of Gene
		Fragments", Methods in Enzymology, 68(6):90-98
	78	Nguyen, Q., et al., 2002, "Identification and Characterization of a Second Novel Human
		Erythrovirus Variant, A6", Virology, 301:374-380
	79	Ozawa, K., et al., 1988, "Functional Mapping of the Genome of the B19 (Human) Parvovirus
		by In Vitro Translation after Negative Hybrid Selection", Journal of Virology, 62(7):2508-2511
	80	Pattison, J., et al., 1981, "Parvovirus Infections and Hypoplastic Crisis in Sickle-Cell
	·	Anaemia", The Lancet, March 21, 1998, pp 664-665
	81	Sambrook, J., et al., 1989, "Molecular Cloning A Laboratory Manual", CSH, 2nd Edition. Cold
		Spring Harbor Laboratory Press.
	82	Sato, K., et al., 2000, "Development of a Hypersensitive Detection Method for Human
		Parvovirus B19 DNA", Journal of Clinical Microbiology, 38(3):1241-1243
	83	Schmidt, J., et al., 2001, "Parvovirus B19 DNA in plasma pools and plasma derivatives", Vox
		Sanguinis, 81: 228-235
	84	Schorling, S., et al., 2004, "Quantification of Parvovirus B19 DNA using COBAS AmpliPrep
		Automated Sample Preparation and LightCycler real-Time PCR", Journal of Molecular
	0.5	Diagnostics, 6(1):37-41
	85	Servant, A., et al., 2002, "Genetic Diversity within Human Erythroviruses: Identification of
	86	Three Genotypes", Journal of Virology, 76(18):9124-9134
	00	Shade, R., et al., 1986, "Nucleotide Sequence and Genome Organization of Human Parvovirus
		B19 Isolated from the Serum of a Child during Aplastic Crisis", <i>Journal of Virology</i> , 58 (<u>3</u>):921-
	87	936 Stold E. et al. 2002 "Evaluation of an Automated Comple Propagation Protocol for
		Stelzl, E., et al., 2002, "Evaluation of an Automated Sample Preparation Protocol for
		Quantitative Detection of Hepatitis C Virus RNA", Journal of Clinical Microbiology, 40 (<u>4</u>):1447-1450
	88	Takahashi, N., et al., 1999, "Genetic heterogeneity of the immunogenic viral capsid protein
		region of human parvovirus B19 isolates obtained from an outbreak in a pediatric ward",
		FEBS Letters, 450:289-293
	89	Turton, J., et al., 1990, "Similarities in nucleotide sequence between serum and faecal human
		parvovirus DNA", Epidemiol. Infect., 105:197-201
<u> </u>	90	Uhlmann, E., et al., 1990, "Antisense Oligonucleotides: A New Therapeutic Principle",
		Chemical Reviews, 90(4):544-584
	91	Umene, K., et al., 1995, "A new genome type of human parvovirus B19 present in sera of
		patients with encephalopathy", Journal of General Virology, 76:2645-2651
L		1

Attorney Docket: 22398-US International Filing Date: February 5, 2005 Serial No. 10/587,386

Page 5 of 5

	92	Vassias, I., et al., 1993, "An in situ hybridization technique for the study of B19 human				
		parvovirus replication in bone marrow cell cultures", Journal of Virological Methods, 44:329-338				
	93	Verma, S., et al., 1998, "Modified Oligonucleotides: Synthesis and Strategy for Users", Annu.				
		Rev. Biochem, 67:99-134				
	94	Vogelstein, B., et al., 1979, "Preparative and analytical purification of DNA from agarose",				
		Proc. Natl. Acad. Sci. USA, 76(2):615-619				
	95	Walsh, C., "Acyl Transfers to Water: Endopeptidases and Exopeptidasses", Enzymatic				
		Reaction Mechanisms, W.H. Freeman and Company San Francisco, Ch. 3 53-107				
	96	Whelen, A., et al., 1996, "The Role of Nucleic Acid Amplification and Detection in the Clinical				
		Microbiology Laboratory", Annu. Rev. Microbiol., 50:349-373				
	97	Wu, D., et al., 1989, "The Ligation Amplification Reaction (LAR) – Amplification of Specific				
		DNA Sequences Using Sequential Rounds of Template-Dependent Ligation", Genomics, 4:560-				
		569				
	98	Yoto, Y., et al., 1996, "Human parvovirus B19 infection associated with acute hepatitis", The				
		Lancet, 347:868-870				
EXAMINER		DATE CONSIDERED				
*EXAMINER conformance ar		if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in onsidered. Include copy of this form with next communication to applicant.				